Compare EPR & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPR | TMDX |
|---|---|---|
| Founded | 1997 | 1998 |
| Country | United States | United States |
| Employees | N/A | 728 |
| Industry | Real Estate Investment Trusts | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.2B |
| IPO Year | 1997 | 2019 |
| Metric | EPR | TMDX |
|---|---|---|
| Price | $50.76 | $122.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | $57.06 | ★ $144.25 |
| AVG Volume (30 Days) | ★ 698.1K | 664.3K |
| Earning Date | 10-29-2025 | 10-29-2025 |
| Dividend Yield | ★ 7.09% | N/A |
| EPS Growth | N/A | ★ 170.70 |
| EPS | 2.29 | ★ 2.54 |
| Revenue | ★ $707,150,000.00 | $566,354,000.00 |
| Revenue This Year | $5.20 | $38.81 |
| Revenue Next Year | $2.95 | $20.49 |
| P/E Ratio | ★ $21.84 | $47.97 |
| Revenue Growth | 3.73 | ★ 41.20 |
| 52 Week Low | $41.75 | $55.00 |
| 52 Week High | $61.24 | $156.00 |
| Indicator | EPR | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 51.40 | 42.70 |
| Support Level | $49.28 | $121.00 |
| Resistance Level | $50.59 | $133.29 |
| Average True Range (ATR) | 0.75 | 4.77 |
| MACD | 0.12 | -0.83 |
| Stochastic Oscillator | 86.78 | 22.79 |
EPR Properties is a real estate investment trust that focuses on underwriting experiential property investments on key industry and property cash flow criteria, and the credit metrics of tenants and customers. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. The Company's business is focused on Experiential real estate. The majority of revenue comes from the Experiential sector.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.